Tbilisi (GBC) - The temporary parliamentary commission studying prices has submitted new recommendations for regulating the pharmaceutical market, which envisage a significant expansion of the reference price system and an average 40% decrease in prices for medicines.

According to the commission's conclusion, the existing practice of setting price caps has already proven its effectiveness, which, while maintaining market stability, has limited excessive margins in the sector.

The parliamentary group is proposing to extend price regulation to at least 60% of actively circulating medicines on the market. According to the commission's forecast, this step will directly affect the consumer's pocket.

"It is advisable to extend the system to at least 60% of actively circulating medicines. As a result, it is expected that the population will receive an average 40% reduction in prices for medicines that are not currently subject to reference prices," the commission's conclusion states.

In parallel, the recommendation envisages a gradual expansion of the state program for the management of chronic diseases. Currently, the program covers 400,000 beneficiaries and its budget is 70 million GEL, although the commission indicates the need to include additional medicines.

To stimulate competition in the market, the document calls for the optimization of the procedures for registering medicines. In particular, it is planned to remove the requirement for bioequivalence studies for those medicines that have been in circulation for more than 10 years under the jurisdiction of the European Medicines Agency (EMA) or other strict regulators.

According to the commission, this change is important for local manufacturers, as it will reduce both financial and time costs. In addition, it is planned to strengthen the national GMP (Good Manufacturing Practice) certification mechanism for foreign manufacturers, which will facilitate the rapid entry of new products into the market.

As part of the reform, the commission calls for the introduction of a unified, coordinated monitoring system. The system should ensure:

  • Continuous analysis of the impact of regulations to avoid reducing the range or withdrawing less profitable medicines from the market
  • Prevention of shortages of medicines by reviewing the terms of contracts with suppliers and ensuring uninterrupted supply

The Commission's conclusion, which aims to improve the value chain, will have a positive impact on price dynamics and product availability in the medium term.